They identified as potential protein biomarkers of paediatric ALL: platelet factor (PF4), connective tissue activating peptide III (CTAP-III) and two fragments of C3a, to differentiate paediatric ALL patients from healthy controls and paediatric AML patients. This evidence concerns the gene C3 and acute lymphoblastic leukemia.